Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Enhancing natural killer cells proliferation and cytotoxicity using imidazole-based lipid nanoparticles encapsulating interleukin-2 mRNA.
Delehedde C, Ciganek I, Bernard PL, Laroui N, Da Silva CC, Gonçalves C, Nunes J, Bennaceur-Griscelli AL, Imeri J, Huyghe M, Even L, Midoux P, Rameix N, Guittard G, Pichon C. Delehedde C, et al. Among authors: guittard g. Mol Ther Nucleic Acids. 2024 Jun 26;35(3):102263. doi: 10.1016/j.omtn.2024.102263. eCollection 2024 Sep 10. Mol Ther Nucleic Acids. 2024. PMID: 39104868 Free PMC article.
Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis.
Le Floch AC, Imbert C, Boucherit N, Gorvel L, Fattori S, Orlanducci F, Le Roy A, Archetti L, Crescence L, Panicot-Dubois L, Dubois C, Vey N, Briantais A, Anastasio A, Cano C, Guittard G, Frechin M, Olive D. Le Floch AC, et al. Among authors: guittard g. Cancer Immunol Res. 2024 Dec 3;12(12):1677-1690. doi: 10.1158/2326-6066.CIR-23-0868. Cancer Immunol Res. 2024. PMID: 39302336
Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors.
Demerlé C, Gorvel L, Mello M, Pastor S, Degos C, Zarubica A, Angelis F, Fiore F, Nunes JA, Malissen B, Greillier L, Guittard G, Luche H, Barlesi F, Olive D. Demerlé C, et al. Among authors: guittard g. J Immunother Cancer. 2023 May;11(5):e006348. doi: 10.1136/jitc-2022-006348. J Immunother Cancer. 2023. PMID: 37230538 Free PMC article.
XIST loss impairs mammary stem cell differentiation and increases tumorigenicity through Mediator hyperactivation.
Richart L, Picod-Chedotel ML, Wassef M, Macario M, Aflaki S, Salvador MA, Héry T, Dauphin A, Wicinski J, Chevrier V, Pastor S, Guittard G, Le Cam S, Kamhawi H, Castellano R, Guasch G, Charafe-Jauffret E, Heard E, Margueron R, Ginestier C. Richart L, et al. Among authors: guittard g. Cell. 2022 Jun 9;185(12):2164-2183.e25. doi: 10.1016/j.cell.2022.04.034. Epub 2022 May 20. Cell. 2022. PMID: 35597241 Free article.
Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity.
Bernard PL, Delconte R, Pastor S, Laletin V, Costa Da Silva C, Goubard A, Josselin E, Castellano R, Krug A, Vernerey J, Devillier R, Olive D, Verhoeyen E, Vivier E, Huntington ND, Nunes J, Guittard G. Bernard PL, et al. Among authors: guittard g. J Immunother Cancer. 2022 May;10(5):e004244. doi: 10.1136/jitc-2021-004244. J Immunother Cancer. 2022. PMID: 35589278 Free PMC article.
TET2 regulates immune tolerance in chronically activated mast cells.
Rigo R, Chelbi R, Agopian J, Letard S, Griffon A, Ghamlouch H, Vernerey J, Ladopoulos V, Voisset E, De Sepulveda P, Guittard G, Nunès JA, Bidaut G, Göttgens B, Weber M, Bernard OA, Dubreuil P, Soucie E. Rigo R, et al. Among authors: guittard g. JCI Insight. 2022 Apr 8;7(7):e154191. doi: 10.1172/jci.insight.154191. JCI Insight. 2022. PMID: 35393954 Free PMC article.
[Unleashing NK cell signaling to improve cancer immunotherapy].
Bernard PL, Laletin V, Pastor S, Nunès JA, Guittard G. Bernard PL, et al. Among authors: guittard g. Med Sci (Paris). 2020 Oct;36 Hors série n° 1:50-55. doi: 10.1051/medsci/2020195. Epub 2020 Oct 14. Med Sci (Paris). 2020. PMID: 33052095 Free article. Review. French. No abstract available.
NK Cell Priming From Endogenous Homeostatic Signals Is Modulated by CIS.
Delconte RB, Guittard G, Goh W, Hediyeh-Zadeh S, Hennessy RJ, Rautela J, Davis MJ, Souza-Fonseca-Guimaraes F, Nunès JA, Huntington ND. Delconte RB, et al. Among authors: guittard g. Front Immunol. 2020 Jan 31;11:75. doi: 10.3389/fimmu.2020.00075. eCollection 2020. Front Immunol. 2020. PMID: 32082327 Free PMC article.
Vitamin D Controls Tumor Growth and CD8+ T Cell Infiltration in Breast Cancer.
Karkeni E, Morin SO, Bou Tayeh B, Goubard A, Josselin E, Castellano R, Fauriat C, Guittard G, Olive D, Nunès JA. Karkeni E, et al. Among authors: guittard g. Front Immunol. 2019 Jun 6;10:1307. doi: 10.3389/fimmu.2019.01307. eCollection 2019. Front Immunol. 2019. PMID: 31244851 Free PMC article.
TP53INP1 deficiency maintains murine B lymphopoiesis in aged bone marrow through redox-controlled IL-7R/STAT5 signaling.
Zidi B, Vincent-Fabert C, Pouyet L, Seillier M, Vandevelde A, N'guessan P, Poplineau M, Guittard G, Mancini SJC, Duprez E, Carrier A. Zidi B, et al. Among authors: guittard g. Proc Natl Acad Sci U S A. 2019 Jan 2;116(1):211-216. doi: 10.1073/pnas.1809980116. Epub 2018 Dec 17. Proc Natl Acad Sci U S A. 2019. PMID: 30559202 Free PMC article.
Unexpected Cartilage Phenotype in CD4-Cre-Conditional SOS-Deficient Mice.
Guittard G, Gallardo DL, Li W, Melis N, Lui JC, Kortum RL, Shakarishvili NG, Huh S, Baron J, Weigert R, Kramer JA, Samelson LE, Sommers CL. Guittard G, et al. Front Immunol. 2017 Mar 23;8:343. doi: 10.3389/fimmu.2017.00343. eCollection 2017. Front Immunol. 2017. PMID: 28386265 Free PMC article.
Ionic immune suppression within the tumour microenvironment limits T cell effector function.
Eil R, Vodnala SK, Clever D, Klebanoff CA, Sukumar M, Pan JH, Palmer DC, Gros A, Yamamoto TN, Patel SJ, Guittard GC, Yu Z, Carbonaro V, Okkenhaug K, Schrump DS, Linehan WM, Roychoudhuri R, Restifo NP. Eil R, et al. Nature. 2016 Sep 22;537(7621):539-543. doi: 10.1038/nature19364. Epub 2016 Sep 14. Nature. 2016. PMID: 27626381 Free PMC article.
Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance.
Palmer DC, Guittard GC, Franco Z, Crompton JG, Eil RL, Patel SJ, Ji Y, Van Panhuys N, Klebanoff CA, Sukumar M, Clever D, Chichura A, Roychoudhuri R, Varma R, Wang E, Gattinoni L, Marincola FM, Balagopalan L, Samelson LE, Restifo NP. Palmer DC, et al. Among authors: guittard gc. J Exp Med. 2015 Nov 16;212(12):2095-113. doi: 10.1084/jem.20150304. Epub 2015 Nov 2. J Exp Med. 2015. PMID: 26527801 Free PMC article.
Enhanced T-cell activation and differentiation in lymphocytes from transgenic mice expressing ubiquitination-resistant 2KR LAT molecules.
Rodriguez-Peña AB, Gomez-Rodriguez J, Kortum RL, Palmer DC, Yu Z, Guittard GC, Wohlfert EA, Silver PB, Misplon JA, Sommers CL, Feigenbaum L, Epstein SL, Caspi RR, Belkaid Y, Restifo NP, Samelson LE, Balagopalan L. Rodriguez-Peña AB, et al. Among authors: guittard gc. Gene Ther. 2015 Oct;22(10):781-92. doi: 10.1038/gt.2015.48. Epub 2015 Jun 18. Gene Ther. 2015. PMID: 26018935 Free PMC article.
An Emerging Role for PI5P in T Cell Biology.
Nunès JA, Guittard G. Nunès JA, et al. Among authors: guittard g. Front Immunol. 2013 Apr 2;4:80. doi: 10.3389/fimmu.2013.00080. eCollection 2013. Front Immunol. 2013. PMID: 23565114 Free PMC article.
Dok-4 is a novel negative regulator of T cell activation.
Gérard A, Ghiotto M, Fos C, Guittard G, Compagno D, Galy A, Lemay S, Olive D, Nunès JA. Gérard A, et al. Among authors: guittard g. J Immunol. 2009 Jun 15;182(12):7681-9. doi: 10.4049/jimmunol.0802203. J Immunol. 2009. PMID: 19494292 Free PMC article.